ArticleTranslational oncology2026
A multi-temporal MRI radiomics model for early post-ablation recurrence risk stratification in hepatocellular carcinoma.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo develop and validate a multi-temporal magnetic resonance imaging (MRI)-based radiomics model for predicting one-year recurrence in hepatocellular carcinoma (HCC) after ablation.
methodsThis retrospective study included 204 patients with HCC who underwent curative ablation between 2016 and 2021. Multi-sequence MRI was performed within one month before and three months after ablation. Radiomics features were extracted from arterial phase (T1A), portal venous phase (T1V), and T2-weighted images using pre-ablation, post-ablation, and delta features. Patients were randomly divided into training (n = 142) and validation (n = 62) cohorts. Models were evaluated using receiver operating characteristic analysis, and differences in AUC between models were assessed.
resultsDuring a median follow-up of 750 days, 50 patients (24.5%) developed recurrence within one year. The integrated radiomics model (IRM) achieved the best discriminatory performance, with area under the curve values of 0.888 (95% CI: 0.801-0.976) in the training cohort and 0.858 (95% CI: 0.718-0.998) in the validation cohort. Kaplan-Meier analysis showed significant differences in recurrence-free survival between IRM-defined low- and high-risk groups in both cohorts (p < 0.001).
conclusionThe multi-temporal MRI radiomics model showed promising performance for early recurrence risk stratification after HCC ablation in the internal validation cohort, suggesting potential translational value for non-invasive recurrence-risk assessment. Further prospective external validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.